IR Department
  • About Us
    • Overview
    • Our Team
    • Our ESG Position
    • Careers
  • Services
    • What We Do
    • Investor Relations
    • IPO Readiness
    • Media Relations
    • Issues and Crisis Communications
    • Digital Content & Social Media Activation
    • Marketing and Brand Campaigns
    • Video Production
    • ESG
    • ESG Competent Boards Masterclass
  • News & Events
    • Blog
  • Contact
    • Contact Us
    • Email Alerts

Recent Posts

  • HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
  • HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
  • Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
  • Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
  • HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025

Archives

  • June 2026
  • May 2026
  • April 2026
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • April 2025
  • March 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • May 2024
  • December 2023
  • October 2023
  • July 2023
  • March 2023
  • February 2023

Categories

  • All
  • AGMs
  • Crisis Communications
  • Equity Insights
  • ESG
  • Investor Relations
  • Newsletter March 2022
  • Newsletter Sept 2022
  • Uncategorized
NEWSLETTER MARCH 2022

08 Mar 2022 · Cherie Hartley

IR Department celebrates International Women's Day 2022

YouTube video player

Read article
NEWSLETTER MARCH 2022

16 Feb 2022 · Paul Langley

Learn more about HaemaLogix’s ground-breaking KappaMab technology

KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.

Read article
  • 1
  • 2

IR Department acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Subscribe


Site Map Privacy Search
IR Department . All rights reserved.